

TIN/NPI Summary Submission Report by Measure Final 2009 Physician Quality Reporting Initiative

Report Date: 10/07/2010

This summary is provided to assist eligible professionals and their staff in interpreting the TIN/NPI Summary Submission Report by Measure. This report outlines the number of TIN/NPIs who are eligible to report the measures, are actually reporting the measures, and have satisfactorily reported the measures.

Column Definitions:

- Reporting Denominator: Applicable Cases - The number of instances the TIN/NPI was eligible to report the measure. The number of eligible denominator instances found in claims.
- Numerator: Valid QDCs Reported - For each measure, the # of instances where a TIN/NPI combination submitted a valid QDC for that measure.
- National Reporting Rate - The # of reported instances divided by the eligible cases.
- # Eligible TIN/NPI - The # of unique TIN/NPI combinations meeting denominator criteria for any of the PQRI measures. This includes only valid occurrences of the denominator.
- # TIN/NPI Submitting - The # of eligible TIN/NPIs that submitted at least one valid, qualifying QDC used appropriately for a measure.
- % Total Eligible TIN/NPI Submitting - The # of TIN/NPI submitting divided by the # of TIN/NPI eligible.
- # TIN/NPI Submitting \geq 80% - The # of TIN/NPIs who submitted the measure on 80% or greater of eligible instances.
- % Submitting \geq 80% - The # of TIN/NPI submitting \geq 80% divided by the # of TIN/NPI submitting.

How to Read the TIN/NPI Summary Submission Report by Measure:

Using Measure #47-Advance Care Plan as an example, we find the following information as we read across each column:

The first three columns after the measure title summarized the overall participant reporting information. 1,202,683 denominator eligible cases were in claims for this measure. 618,805 of which were reported with a quality-data code (QDC) for the measure. Therefore, the national reporting rate for all TIN/NPIs reporting this measure is 51.45%. 616,182 TIN/NPIs could have reported on this measure based on claims that were denominator eligible. Of those TIN/NPIs, 6,234 (1.01%) TIN/NPIs actually submitted a QDC for the measure. 2,253 (36.14%) of the TIN/NPIs submitting a QDC for the measure had a reporting rate of 80% or above.

Analysis Findings Include:

1. The 5 measures with the highest number of eligible professionals were:
 - #128 Universal Weight Screening and Follow-Up (782,184),
 - #130 Documentation of Current Medications (768,025),
 - #124 HIT - Adoption/Use of EHRs (756,805),
 - #114 Inquiry Regarding Tobacco Use (646,182), and
 - #173 Preventive Care and Screening: Unhealthy Alcohol Use - Screening (625,374).

2. The 5 measures with the highest number of TIN/NPIs submitting were:
 - #54 ECG Performed for Non-Traumatic Chest Pain (37,688),
 - #57 Assessment of Oxygen Saturation for Community-Acquired Bacterial Pneumonia (36,197),
 - #58 Assessment of Mental Status for Community-Acquired Bacterial Pneumonia (32,199),
 - #56 Vital Signs for Community-Acquired Bacterial Pneumonia (32,131), and
 - #55 ECG Performed for Syncope (31,548).
3. There were 46 measures where the submission rate of eligible providers was less than 1%. The lowest 5 submission rates for measures with at least one valid QDC submitted were:
 - #181 Elder Maltreatment Screen and Follow-Up Plan (0.05%),
 - #116 Avoidance of Inappropriate Antibiotic Treatment for Adults (0.06%),
 - #173 Preventive Care and Screening: Unhealthy Alcohol Use - Screening (0.11%),
 - #179 Rheumatoid Arthritis (RA): Assessment and Classification of Disease Prognosis (0.13%), and
 - #180 Rheumatoid Arthritis (RA): Glucocorticoid Management (0.14%).
4. Four Measures with no valid QDCs submitted were:
 - #175 Pediatric End Stage Renal Disease (ESRD): Influenza Immunization (0/252)
 - #94 OME: Diagnostic Evaluation - Assessment of Tympanic Membrane Mobility (0/21)
 - #95 OME: Hearing Testing (0/9)
 - #66 Appropriate Testing for Children (0/144).
5. Of submitting TIN/NPIs, the top 5 measures with the greatest proportion of TIN/NPIs submitting at or above 80% were:
 - #65 Appropriate Treatment for Children (100.00%- based on one TIN/NPI),
 - #144 Oncology: Medical and Radiation - Plan of Care for Pain (87.35%),
 - #58 Assessment of Mental Status for Community-Acquired Bacterial Pneumonia (82.09%),
 - #55 ECG Performed for Syncope (81.64%), and
 - #57 Assessment of Oxygen Saturation for Community-Acquired Bacterial Pneumonia (81.02%).

TIN/NPI Summary Submission Report by Measure
 Report Includes Data from the January 2009 through February 2010 TAP File

Clinical Condition and Measure	Participant Reporting Information			# Eligible TIN/NPI ^d	TIN/NPI Participation per Measure		# TIN/NPI Submitting $\geq 80\%$ ^g	% Submitting $\geq 80\%$ ^h
	Reporting Denominator: Applicable Cases ^a	Numerator: Valid QDCs Reported ^b	National Reporting Rate ^c		# TIN/NPI Submitting ^e	% Total Eligible TIN/NPI Submitting ^f		
Advance Care Plan				616,182	6,234	1.01%		
#47 Advance Care Plan	1,202,683	618,805	51.45%	616,182	6,234	1.01%	2,253	36.14%
Arthritis-Osteoarthritis				212,924	1,046	0.49%		
#109 Patients with OA with an Assessment of Pain and Function	162,792	70,063	43.04%	212,924	750	0.35%	177	23.60%
#142 Osteoarthritis (OA): Assessment for Use of Anti-Inflammatory or Analgesic Over-the-Counter (OTC) Medications	107,146	36,758	34.31%	212,924	565	0.27%	105	18.58%
Arthritis-Rheumatoid				144,323	682	0.47%		
#108 DMARD Therapy in Rheumatoid Arthritis	53,934	30,477	56.51%	144,323	653	0.45%	261	39.97%
#176 Rheumatoid Arthritis (RA): Tuberculosis Screening	21,440	6,118	28.54%	130,334	192	0.15%	34	17.71%
#177 Rheumatoid Arthritis (RA): Periodic Assessment of Disease Activity	22,756	7,322	32.18%	130,334	189	0.15%	29	15.34%
#178 Rheumatoid Arthritis (RA): Functional Status Assessment	24,900	9,307	37.38%	130,333	219	0.17%	47	21.46%
#179 Rheumatoid Arthritis (RA): Assessment and Classification of Disease Prognosis	20,145	6,002	29.79%	130,333	164	0.13%	21	12.80%
#180 Rheumatoid Arthritis (RA): Glucocorticoid Management	20,424	5,950	29.13%	130,333	180	0.14%	30	16.67%
Asthma				48,882	490	1.00%		
#53 Pharmacologic Therapy	927	693	74.76%	48,882	443	0.91%	329	74.27%
#64 Asthma Assessment	605	478	79.01%	48,882	277	0.57%	201	72.56%
Breast Cancer				523,348	11,900	2.27%		
#71 Hormonal Therapy for Stage IC-III ER/PR Positive Breast Cancer	102,349	55,376	54.11%	104,055	1,595	1.53%	510	31.97%

^a The number of instances the TIN/NPI was eligible to report the measure. The number of eligible denominator instances found in claims.

^b For each measure, the # of instances where an TIN/NPI combination submitted a valid QDC for that measure.

^c The # of reported instances divided by the eligible cases.

^d The # of unique TIN/NPI combinations meeting denominator criteria for any of the PQRI measures. This includes only valid occurrences of the denominator.

^e The # of eligible NPIs that submitted at least one valid, qualifying QDC used appropriately for a measure.

^f The # of TIN/NPI submitting divided by the # of TIN/NPI eligible.

^g The # of TIN/NPIs who submitted the measure on 80% or greater of eligible instances.

^h The # of TIN/NPI submitting $\geq 80\%$ divided by the # of TIN/NPI submitting.

ⁱ Unduplicated counts of TIN/NPIs (I.e. Clinical Condition/Topic and National totals are a unique count of all TIN/NPIs).

Note: The grayed-out cells do not have a calculated national total.

Note: MCMP and PGP pilot program participants are excluded from these reports (based on the most recent pilot participant list from ORD).

Clinical Condition and Measure	Participant Reporting Information			# Eligible TIN/NPI ^d	TIN/NPI Participation per Measure		# TIN/NPI Submitting $\geq 80\%$ ^g	% Submitting $\geq 80\%$ ^h
	Reporting Denominator: Applicable Cases ^a	Numerator: Valid QDCs Reported ^b	National Reporting Rate ^c		# TIN/NPI Submitting ^e	% Total Eligible TIN/NPI Submitting ^f		
Breast Cancer				523,348	11,900	2.27%		
#99 Breast Cancer Patients with a pT and pN Category and Histologic Grade	38,743	29,961	77.33%	7,241	4,373	60.39%	2,770	63.34%
#112 Screening Mammography	266,482	108,786	40.82%	515,673	6,007	1.16%	2,244	37.36%
Bronchitis				99,500	55	0.06%		
#116 Inappropriate Antibiotic Treatment for Adults	506	93	18.38%	99,500	55	0.06%	15	27.27%
Coronary Artery Bypass Graft (CABG)				4,061	1,093	26.91%		
#43 Use of IMA in CABG Surgery	30,573	24,242	79.29%	4,061	1,088	26.79%	788	72.43%
#44 Preoperative Beta-blocker in Patients with Isolated CABG Surgery	21,449	16,480	76.83%	4,061	786	19.35%	551	70.10%
CAD				246,248	14,720	5.98%		
#6 Oral Antiplatelet Therapy Prescribed for Patients with CAD	1,590,284	1,195,345	75.17%	246,248	14,341	5.82%	7,829	54.59%
#118 ACE or ARB Therapy for Patients with CAD and Diabetes and/or LVSD	310,595	154,181	49.64%	221,571	1,902	0.86%	571	30.02%
#152 Coronary Artery Disease (CAD): Lipid Profile in Patients with CAD	488,830	338,085	69.16%	219,487	2,726	1.24%	1,310	48.06%
Chest Pain				65,570	37,688	57.48%		
#54 ECG Performed for Non-Traumatic Chest Pain	1,267,908	1,058,296	83.47%	65,570	37,688	57.48%	29,255	77.62%
Chronic Kidney Disease (CKD)				45,994	884	1.92%		
#121 Laboratory Testing (Calcium, Phosphorus, iPTH and Lipid Profile)	26,448	13,481	50.97%	45,994	554	1.20%	203	36.64%
#122 Blood Pressure Management	73,873	39,017	52.82%	45,994	721	1.57%	298	41.33%
#123 Plan of Care: Elevated Hemoglobin for Patients Receiving ESAs	63,111	29,149	46.19%	45,994	604	1.31%	192	31.79%
#135 Chronic Kidney Disease (CKD): Influenza Immunization	19,270	9,317	48.35%	45,994	422	0.92%	146	34.60%
#153 Chronic Kidney Disease (CKD): Referral for Arteriovenous (AV) Fistula	16,409	7,013	42.74%	45,994	304	0.66%	80	26.32%

^a The number of instances the TIN/NPI was eligible to report the measure. The number of eligible denominator instances found in claims.

^b For each measure, the # of instances where an TIN/NPI combination submitted a valid QDC for that measure.

^c The # of reported instances divided by the eligible cases.

^d The # of unique TIN/NPI combinations meeting denominator criteria for any of the PQRI measures. This includes only valid occurrences of the denominator.

^e The # of eligible NPIs that submitted at least one valid, qualifying QDC used appropriately for a measure.

^f The # of TIN/NPI submitting divided by the # of TIN/NPI eligible.

^g The # of TIN/NPIs who submitted the measure on 80% or greater of eligible instances.

^h The # of TIN/NPI submitting $\geq 80\%$ divided by the # of TIN/NPI submitting.

ⁱ Unduplicated counts of TIN/NPIs (i.e. Clinical Condition/Topic and National totals are a unique count of all TIN/NPIs).

Note: The grayed-out cells do not have a calculated national total.

Note: MCMP and PGP pilot program participants are excluded from these reports (based on the most recent pilot participant list from ORD).)

Clinical Condition and Measure	Participant Reporting Information			# Eligible TIN/NPI ^d	TIN/NPI Participation per Measure		# TIN/NPI Submitting $\geq 80\%$ ^g	% Submitting $\geq 80\%$ ^h
	Reporting Denominator: Applicable Cases ^a	Numerator: Valid QDCs Reported ^b	National Reporting Rate ^c		# TIN/NPI Submitting ^e	% Total Eligible TIN/NPI Submitting ^f		
Colon Cancer				68,598	1,253	1.83%		
#72 Chemotherapy for Stage III	26,652	15,475	58.06%	68,598	1,253	1.83%	381	30.41%
Colorectal Cancer (CRC)				570,449	10,639	1.87%		
#100 CRC Patients with a pT and pN Category and Histologic Grade	21,038	17,690	84.09%	6,843	4,201	61.39%	3,192	75.98%
#113 CRC Screening	1,007,420	370,473	36.77%	563,724	6,438	1.14%	2,435	37.82%
Chronic Obstructive Pulmonary Disease (COPD)				212,885	1,960	0.92%		
#51 Spirometry Evaluation	143,754	83,977	58.42%	212,885	1,841	0.86%	737	40.03%
#52 Bronchodilator Therapy	115,357	64,730	56.11%	212,885	1,336	0.63%	424	31.74%
Cataracts				24,667	3,099	12.56%		
#139 Cataracts: Comprehensive Preoperative Assessment for Cataract Surgery with Intraocular Lens (IOL) Placement	630,756	523,904	83.06%	24,667	3,099	12.56%	2,230	71.96%
Catheter-Related Bloodstream Infections (CRBSI)				91,055	9,085	9.98%		
#76 Prevention of CRBSI - Central Venous Catheter Insertion Protocol	210,601	151,503	71.94%	91,055	9,085	9.98%	5,418	59.64%
Chiropractic Care				47,529	145	0.31%		
#182 Functional Outcome Assessment in Chiropractic Care	116,890	32,006	27.38%	47,529	145	0.31%	16	11.03%
Depression				252,354	935	0.37%		
#9 Antidepressant Meds During Acute Phase for Patients with New Episode of MD	26,050	12,849	49.32%	252,354	761	0.30%	227	29.83%
#106 Patients who have MD Disorder who meet DSM IV Criteria	10,310	6,102	59.19%	104,942	386	0.37%	146	37.82%
#107 Patients who have MD Disorder who are Assessed for Suicide Risks	35,503	20,617	58.07%	104,942	436	0.42%	144	33.03%
Diabetes				375,887	33,266	8.85%		
#1 Hemoglobin A1c Poor Control	686,808	429,581	62.55%	309,869	20,277	6.54%	10,086	49.74%
#2 Low Density Lipoprotein Control	645,515	399,651	61.91%	309,869	19,354	6.25%	9,620	49.71%
#3 High Blood Pressure Control	641,055	400,509	62.48%	309,869	18,722	6.04%	9,165	48.95%

^a The number of instances the TIN/NPI was eligible to report the measure. The number of eligible denominator instances found in claims.

^b For each measure, the # of instances where an TIN/NPI combination submitted a valid QDC for that measure.

^c The # of reported instances divided by the eligible cases.

^d The # of unique TIN/NPI combinations meeting denominator criteria for any of the PQR measures. This includes only valid occurrences of the denominator.

^e The # of eligible NPIs that submitted at least one valid, qualifying QDC used appropriately for a measure.

^f The # of TIN/NPI submitting divided by the # of TIN/NPI eligible.

^g The # of TIN/NPIs who submitted the measure on 80% or greater of eligible instances.

^h The # of TIN/NPI submitting $\geq 80\%$ divided by the # of TIN/NPI submitting.

ⁱ Unduplicated counts of TIN/NPIs (i.e. Clinical Condition/Topic and National totals are a unique count of all TIN/NPIs).

Note: The grayed-out cells do not have a calculated national total.

Note: MCMP and PGP pilot program participants are excluded from these reports (based on the most recent pilot participant list from ORD).

Clinical Condition and Measure	Participant Reporting Information			# Eligible TIN/NPI ^d	TIN/NPI Participation per Measure		# TIN/NPI Submitting $\geq 80\%$ ^g	% Submitting $\geq 80\%$ ^h
	Reporting Denominator: Applicable Cases ^a	Numerator: Valid QDCs Reported ^b	National Reporting Rate ^c		# TIN/NPI Submitting ^e	% Total Eligible TIN/NPI Submitting ^f		
Diabetes				375,887	33,266	8.85%		
#18 Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy	406,323	280,769	69.10%	45,222	8,122	17.96%	3,635	44.75%
#19 Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care	211,222	131,808	62.40%	45,222	4,097	9.06%	1,629	39.76%
#117 Dilated Eye Exam in Diabetic Patient	642,329	389,939	60.71%	325,257	10,669	3.28%	3,747	35.12%
#119 Urine Screening for Microalbumin or Medical Attention for Nephropathy in Diabetic Patients	161,139	69,855	43.35%	309,869	4,062	1.31%	1,195	29.42%
#126 Diabetic Foot and Ankle Care, Peripheral Neuropathy: Neurological Evaluation	155,100	64,601	41.65%	357,655	1,814	0.51%	464	25.58%
#127 Diabetic Foot and Ankle Care, Ulcer Prevention: Evaluation of Footwear	114,459	48,179	42.09%	357,655	1,173	0.33%	266	22.68%
#163 Diabetes Mellitus: Foot Exam	124,557	52,976	42.53%	309,869	2,787	0.90%	516	18.51%
Elder Care				65,234	31	0.05%		
#181 Elder Maltreatment Screen and Follow-Up Plan	2,176	1,319	60.62%	65,234	31	0.05%	11	35.48%
End Stage Renal Disease (ESRD)				9,317	248	2.66%		
#79 Influenza Vaccination in Patients with ESRD	41,581	25,298	60.84%	9,261	248	2.68%	103	41.53%
#175 Pediatric End Stage Renal Disease (ESRD): Influenza Immunization	0		0.00%	252	0	0.00%	0	0.00%
Endarterectomy				6,728	258	3.83%		
#158 Endarterectomy: Use of Patch During Conventional Endarterectomy	3,795	2,476	65.24%	6,728	258	3.83%	127	49.22%
Endoscopy and Polyp Surveillance				16,478	585	3.55%		
#185 Endoscopy & Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps - Avoidance of Inappropriate Use	29,565	20,919	70.76%	16,478	585	3.55%	285	48.72%
Falls				605,832	7,957	1.31%		
#154 Falls: Risk Assessment	910,507	329,777	36.22%	605,832	7,951	1.31%	2,278	28.65%
#155 Falls: Plan of Care	46,431	37,287	80.31%	6,810	3,183	46.74%	2,262	71.07%

^a The number of instances the TIN/NPI was eligible to report the measure. The number of eligible denominator instances found in claims.

^b For each measure, the # of instances where an TIN/NPI combination submitted a valid QDC for that measure.

^c The # of reported instances divided by the eligible cases.

^d The # of unique TIN/NPI combinations meeting denominator criteria for any of the PQRI measures. This includes only valid occurrences of the denominator.

^e The # of eligible NPIs that submitted at least one valid, qualifying QDC used appropriately for a measure.

^f The # of TIN/NPI submitting divided by the # of TIN/NPI eligible.

^g The # of TIN/NPIs who submitted the measure on 80% or greater of eligible instances.

^h The # of TIN/NPI submitting $\geq 80\%$ divided by the # of TIN/NPI submitting.

ⁱ Unduplicated counts of TIN/NPIs (i.e. Clinical Condition/Topic and National totals are a unique count of all TIN/NPIs).

Note: The grayed-out cells do not have a calculated national total.

Note: MCMP and PGP pilot program participants are excluded from these reports (based on the most recent pilot participant list from ORD).

Clinical Condition and Measure	Participant Reporting Information			# Eligible TIN/NPI ^d	TIN/NPI Participation per Measure		# TIN/NPI Submitting $\geq 80\%$ ^g	% Submitting $\geq 80\%$ ^h
	Reporting Denominator: Applicable Cases ^a	Numerator: Valid QDCs Reported ^b	National Reporting Rate ^c		# TIN/NPI Submitting ^e	% Total Eligible TIN/NPI Submitting ^f		
Glaucoma				46,182	10,368	22.45%		
#12 Optic Nerve Evaluation	1,365,415	1,051,406	77.00%	46,182	10,293	22.29%	5,463	53.07%
#141 Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% OR Documentation of a Plan of Care	274,286	160,838	58.64%	43,406	2,766	6.37%	1,078	38.97%
Heart Failure				235,346	10,794	4.59%		
#5 ACE Inhibitor or ARB Therapy for LVSD	374,202	242,227	64.73%	235,346	10,180	4.33%	4,488	44.09%
#8 Beta-blocker Therapy for LVSD	282,892	196,030	69.29%	207,643	6,491	3.13%	3,401	52.40%
Hemodialysis Vascular Access Decision				4,920	125	2.54%		
#172 Hemodialysis Vascular Access Decision-Making by Surgeon to Maximize Placement of Autogenous Arterial Venous (AV) Fistula	3,540	1,962	55.42%	4,920	125	2.54%	44	35.20%
Hepatitis C (HCV)				65,779	544	0.83%		
#83 Testing of Patients with Chronic HCV for Hepatitis C Viremia	4,543	2,680	58.99%	65,779	310	0.47%	91	29.35%
#84 Initial Hepatitis C RNA Testing	2,971	1,985	66.81%	34,793	228	0.66%	97	42.54%
#85 Genotype Testing Prior to Therapy	3,648	2,316	63.49%	34,793	238	0.68%	105	44.12%
#86 Consideration for Antiviral Therapy	1,959	1,095	55.90%	34,793	154	0.44%	60	38.96%
#87 RNA Testing at Week 12 of Therapy	1,078	585	54.27%	34,793	104	0.30%	37	35.58%
#89 Counseling Patients Regarding Use of Alcohol	2,035	988	48.55%	65,779	247	0.38%	80	32.39%
#90 Counseling Patients Regarding Use of Contraception Prior to Starting Antiviral Therapy	402	197	49.00%	25,184	58	0.23%	20	34.48%
#183 Hepatitis C: Hepatitis A Vaccination in Patients with HCV	1,892	942	49.79%	55,376	192	0.35%	83	43.23%
#184 Hepatitis C: Hepatitis B Vaccination in Patients with HCV	1,941	962	49.56%	55,375	196	0.35%	86	43.88%
HIT				756,805	26,691	3.53%		
#124 HIT - Adoption/Use of EHRs	13,831,196	8,201,597	59.30%	756,805	26,691	3.53%	13,075	48.99%

^a The number of instances the TIN/NPI was eligible to report the measure. The number of eligible denominator instances found in claims.

^b For each measure, the # of instances where an TIN/NPI combination submitted a valid QDC for that measure.

^c The # of reported instances divided by the eligible cases.

^d The # of unique TIN/NPI combinations meeting denominator criteria for any of the PQRI measures. This includes only valid occurrences of the denominator.

^e The # of eligible NPIs that submitted at least one valid, qualifying QDC used appropriately for a measure.

^f The # of TIN/NPI submitting divided by the # of TIN/NPI eligible.

^g The # of TIN/NPIs who submitted the measure on 80% or greater of eligible instances.

^h The # of TIN/NPI submitting $\geq 80\%$ divided by the # of TIN/NPI submitting.

ⁱ Unduplicated counts of TIN/NPIs (i.e. Clinical Condition/Topic and National totals are a unique count of all TIN/NPIs).

Note: The grayed-out cells do not have a calculated national total.

Note: MCMP and PGP pilot program participants are excluded from these reports (based on the most recent pilot participant list from ORDJ).

Clinical Condition and Measure	Participant Reporting Information			# Eligible TIN/NPI ^d	TIN/NPI Participation per Measure		# TIN/NPI Submitting $\geq 80\%$ ^g	% Submitting $\geq 80\%$ ^h
	Reporting Denominator: Applicable Cases ^a	Numerator: Valid QDCs Reported ^b	National Reporting Rate ^c		# TIN/NPI Submitting ^e	% Total Eligible TIN/NPI Submitting ^f		
Imaging-Stroke				53,267	10,110	18.98%		
#10 CT or MRI Reports	468,081	296,856	63.42%	34,232	9,011	26.32%	3,864	42.88%
#11 Carotid Imaging Reports	113,275	74,234	65.53%	41,853	6,971	16.66%	3,099	44.46%
Influenza				561,256	6,423	1.14%		
#110 Vaccination for Patients ≥ 50 Years Old	1,463,771	492,461	33.64%	561,256	6,423	1.14%	1,496	23.29%
Leukemia (CLL)				34,667	1,630	4.70%		
#70 Baseline Flow Cytometry	20,350	14,157	69.57%	34,667	1,630	4.70%	814	49.94%
Macular Degeneration				70,771	10,732	15.16%		
#14 Dilated Macular Examination	1,226,130	926,943	75.60%	70,771	10,349	14.62%	5,183	50.08%
#140 Age-Related Macular Degeneration (AMD): Counseling on Antioxidant Supplement	715,379	487,664	68.17%	70,352	5,329	7.57%	2,066	38.77%
Myelodysplastic Syndrome (MDS) and Acute Leukemias				26,875	1,687	6.28%		
#67 Baseline Cytogenetic Testing Performed on Bone Marrow	23,795	15,014	63.10%	26,875	1,332	4.96%	528	39.64%
#68 Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy	21,300	13,204	61.99%	21,607	1,235	5.72%	452	36.60%
Medication Management				768,025	11,229	1.46%		
#130 Documentation of Current Medications	4,365,021	2,227,183	51.02%	768,025	11,229	1.46%	4,136	36.83%
Melanoma				53,068	2,250	4.24%		
#136 Melanoma: Follow-Up Aspects of Care	71,846	51,928	72.28%	53,068	2,202	4.15%	1,056	47.96%
#137 Melanoma: Continuity of Care - Recall System	68,670	50,393	73.38%	53,068	2,034	3.83%	1,003	49.31%
#138 Melanoma: Coordination of Care	17,490	8,924	51.02%	44,896	891	1.98%	321	36.03%
Mental Health				116,322	340	0.29%		
#134 Screening for Clinical Depression	13,788	7,599	55.11%	116,322	340	0.29%	122	35.88%
Myeloma				34,282	1,777	5.18%		
#69 Treatment with Bisphosphonates	16,667	10,744	64.46%	34,282	1,777	5.18%	781	43.95%
Myocardial Infarction				30,421	14,928	49.07%		
#28 Aspirin at Arrival	58,790	49,682	84.51%	30,421	14,928	49.07%	11,909	79.78%

^a The number of instances the TIN/NPI was eligible to report the measure. The number of eligible denominator instances found in claims.

^b For each measure, the # of instances where an TIN/NPI combination submitted a valid QDC for that measure.

^c The # of reported instances divided by the eligible cases.

^d The # of unique TIN/NPI combinations meeting denominator criteria for any of the PQRI measures. This includes only valid occurrences of the denominator.

^e The # of eligible NPIs that submitted at least one valid, qualifying QDC used appropriately for a measure.

^f The # of TIN/NPI submitting divided by the # of TIN/NPI eligible.

^g The # of TIN/NPIs who submitted the measure on 80% or greater of eligible instances.

^h The # of TIN/NPI submitting $\geq 80\%$ divided by the # of TIN/NPI submitting.

ⁱ Unduplicated counts of TIN/NPIs (i.e. Clinical Condition/Topic and National totals are a unique count of all TIN/NPIs).

Note: The grayed-out cells do not have a calculated national total.

Note: MCMP and PGP pilot program participants are excluded from these reports (based on the most recent pilot participant list from ORDI).

Clinical Condition and Measure	Participant Reporting Information			# Eligible TIN/NPI ^d	TIN/NPI Participation per Measure		# TIN/NPI Submitting $\geq 80\%$ ^g	% Submitting $\geq 80\%$ ^h
	Reporting Denominator: Applicable Cases ^a	Numerator: Valid QDCs Reported ^b	National Reporting Rate ^c		# TIN/NPI Submitting ^e	% Total Eligible TIN/NPI Submitting ^f		
Nuclear Medicine				19,215	4,310	22.43%		
#147 Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy	121,526	86,686	71.33%	19,215	4,310	22.43%	2,759	64.01%
Obesity				782,184	6,009	0.77%		
#128 Universal Weight Screening and Follow-Up	1,291,085	387,247	29.99%	782,184	6,009	0.77%	1,185	19.72%
Oncology				20,881	591	2.83%		
#143 Oncology: Medical and Radiation - Pain Intensity Quantified	133,179	69,836	52.44%	20,855	398	1.91%	117	29.40%
#144 Oncology: Medical and Radiation - Plan of Care for Pain	18,518	16,853	91.01%	331	324	97.89%	283	87.35%
#156 Oncology: Radiation Dose Limits to Normal Tissues	2,622	1,567	59.76%	3,706	249	6.72%	98	39.36%
Osteoporosis				533,601	9,716	1.82%		
#24 Communication with the Physician Managing Ongoing Care Post-Fracture	16,649	7,776	46.71%	115,342	828	0.72%	258	31.16%
#39 Screening or Therapy for Women Aged 65 Years and Older	834,961	344,969	41.32%	521,391	7,258	1.39%	2,789	38.43%
#40 Management Following Fracture	14,646	5,405	36.90%	115,342	1,308	1.13%	507	38.76%
#41 Pharmacologic Therapy	120,945	66,347	54.86%	182,332	3,811	2.09%	1,809	47.47%
Otitis				87,388	279	0.32%		
#91 AOE: Topical Therapy	5,271	3,288	62.38%	87,373	250	0.29%	83	33.20%
#92 AOE: Pain Assessment	4,925	2,636	53.52%	87,373	186	0.21%	65	34.95%
#93 AOE: Systemic Antimicrobial Therapy – Avoidance of Inappropriate Use	4,001	2,168	54.19%	87,373	193	0.22%	62	32.12%
#94 OME: Diagnostic Evaluation – Assessment of Tympanic Membrane Mobility	0	0	0.00%	21	0	0.00%	0	0.00%
#95 OME: Hearing Testing	0	0	0.00%	9	0	0.00%	0	0.00%

^a The number of instances the TIN/NPI was eligible to report the measure. The number of eligible denominator instances found in claims.

^b For each measure, the # of instances where an TIN/NPI combination submitted a valid QDC for that measure.

^c The # of reported instances divided by the eligible cases.

^d The # of unique TIN/NPI combinations meeting denominator criteria for any of the PQRI measures. This includes only valid occurrences of the denominator.

^e The # of eligible NPIs that submitted at least one valid, qualifying QDC used appropriately for a measure.

^f The # of TIN/NPI submitting divided by the # of TIN/NPI eligible.

^g The # of TIN/NPIs who submitted the measure on 80% or greater of eligible instances.

^h The # of TIN/NPI submitting $\geq 80\%$ divided by the # of TIN/NPI submitting.

ⁱ Unduplicated counts of TIN/NPIs (i.e. Clinical Condition/Topic and National totals are a unique count of all TIN/NPIs).

Note: The grayed-out cells do not have a calculated national total.

Note: MCMP and PGP pilot program participants are excluded from these reports (based on the most recent pilot participant list from ORDJ).

Clinical Condition and Measure	Participant Reporting Information			# Eligible TIN/NPI ^d	TIN/NPI Participation per Measure		# TIN/NPI Submitting ≥80% ^g	% Submitting ≥80% ^h
	Reporting Denominator: Applicable Cases ^a	Numerator: Valid QDCs Reported ^b	National Reporting Rate ^c		# TIN/NPI Submitting ^e	% Total Eligible TIN/NPI Submitting ^f		
Pain Management				167,374	5,459	3.26%		
#131 Assessment Prior to Initiation of Patient Treatment	526,271	231,453	43.98%	167,374	5,459	3.26%	2,576	47.19%
Perioperative				194,015	39,900	20.57%		
#20 Timing of Antibiotic Prophylaxis - Ordering Physician	407,711	275,446	67.56%	102,520	8,037	7.84%	4,115	51.20%
#21 Selection of Prophylactic Antibiotic - First OR Second Generation Cephalosporin	302,541	203,297	67.20%	73,193	5,929	8.10%	2,955	49.84%
#22 Discontinuation of Prophylactic Antibiotics (Non-Cardiac Procedures)	193,236	125,759	65.08%	94,782	4,342	4.58%	2,076	47.81%
#23 VTE Prophylaxis	215,023	142,383	66.22%	78,242	4,986	6.37%	2,493	50.00%
#30 Timing of Prophylactic Antibiotics - Administering Physician	3,360,142	2,409,905	71.72%	81,830	31,154	38.07%	17,224	55.29%
#45 Discontinuation of Prophylactic Antibiotics	77,353	56,549	73.11%	4,448	757	17.02%	471	62.22%
Pharyngitis				144	0	0.00%		
#66 Appropriate Testing for Children	0	0	0.00%	144	0	0.00%	0	0.00%
Pneumonia				203,563	38,168	18.75%		
#56 Vital Signs for Community-Acquired Bacterial Pneumonia	526,593	454,929	86.39%	203,563	32,131	15.78%	25,868	80.51%
#57 Assessment of Oxygen Saturation for Community-Acquired Bacterial Pneumonia	578,432	501,569	86.71%	203,563	36,197	17.78%	29,327	81.02%
#58 Assessment of Mental Status for Community-Acquired Bacterial Pneumonia	515,439	446,970	86.72%	203,563	32,199	15.82%	26,431	82.09%
#59 Empiric Antibiotic for Community-Acquired Bacterial Pneumonia	367,937	303,996	82.62%	203,563	22,677	11.14%	17,233	75.99%
Pneumonia Pneumococcal				567,994	6,440	1.13%		
#111 Vaccination for Patients 65 years and Older	1,366,374	550,646	40.30%	567,994	6,440	1.13%	1,994	30.96%
Preventive Care and Screening				625,374	662	0.11%		
#173 Preventive Care and Screening: Unhealthy Alcohol Use - Screening	115,737	44,747	38.66%	625,374	662	0.11%	152	22.96%

^a The number of instances the TIN/NPI was eligible to report the measure. The number of eligible denominator instances found in claims.

^b For each measure, the # of instances where an TIN/NPI combination submitted a valid QDC for that measure.

^c The # of reported instances divided by the eligible cases.

^d The # of unique TIN/NPI combinations meeting denominator criteria for any of the PQR measures. This includes only valid occurrences of the denominator.

^e The # of eligible NPIs that submitted at least one valid, qualifying QDC used appropriately for a measure.

^f The # of TIN/NPI submitting divided by the # of TIN/NPI eligible.

^g The # of TIN/NPIs who submitted the measure on 80% or greater of eligible instances.

^h The # of TIN/NPI submitting ≥80% divided by the # of TIN/NPI submitting.

ⁱ Unduplicated counts of TIN/NPIs (i.e. Clinical Condition/Topic and National totals are a unique count of all TIN/NPIs).

Note: The grayed-out cells do not have a calculated national total.

Note: MCMP and PGP pilot program participants are excluded from these reports (based on the most recent pilot participant list from ORD).

Clinical Condition and Measure	Participant Reporting Information			# Eligible TIN/NPI ^d	TIN/NPI Participation per Measure		# TIN/NPI Submitting $\geq 80\%$ ^g	% Submitting $\geq 80\%$ ^h
	Reporting Denominator: Applicable Cases ^a	Numerator: Valid QDCs Reported ^b	National Reporting Rate ^c		# TIN/NPI Submitting ^e	% Total Eligible TIN/NPI Submitting ^f		
Prostate Cancer				8,146	717	8.80%		
#102 Inappropriate Use of Bone Scan for Staging Low-Risk Prostate Cancer Patients	10,201	4,477	43.89%	8,138	471	5.79%	163	34.61%
#104 Adjuvant Hormonal Therapy for High-Risk Prostate Cancer Patients	9,443	3,857	40.85%	4,114	431	10.48%	101	23.43%
#105 Three-dimensional Radiotherapy for Patients with Prostate Cancer	9,277	4,954	53.40%	4,023	506	12.58%	179	35.38%
Radiology				139,467	9,347	6.70%		
#145 Radiology: Exposure Time Reported for Procedures Using Fluoroscopy	863,616	545,901	63.21%	127,845	7,453	5.83%	3,408	45.73%
#146 Radiology: Inappropriate Use of "Probably Benign" Assessment Category in Mammography Screening	1,774,410	1,276,369	71.93%	28,696	5,651	19.69%	3,553	62.87%
Stroke and Stroke Rehabilitation				126,430	4,432	3.51%		
#31 DVT Prophylaxis for Ischemic Stroke or Intracranial Hemorrhage	17,040	10,259	60.21%	96,183	1,778	1.85%	801	45.05%
#32 Discharged on Antiplatelet Therapy	29,428	16,801	57.09%	92,235	2,932	3.18%	1,343	45.80%
#34 t-PA Considered	12,421	7,343	59.12%	84,442	1,551	1.84%	859	55.38%
#35 Screening for Dysphagia	9,880	5,330	53.95%	73,631	940	1.28%	367	39.04%
#36 Consideration of Rehabilitation Services	21,650	12,894	59.56%	71,258	2,418	3.39%	1,139	47.11%
Syncope				52,049	31,548	60.61%		
#55 ECG Performed for Syncope	375,443	323,549	86.18%	52,049	31,548	60.61%	25,756	81.64%
Thoracic Surgery				3,297	43	1.30%		
#157 Thoracic Surgery: Recording of Clinical Stage for Lung Cancer and Esophageal Cancer Resection	877	569	64.88%	3,297	43	1.30%	18	41.86%
Tobacco Use				672,751	14,074	2.09%		
#114 Inquiry Regarding Tobacco Use	2,975,498	1,415,970	47.59%	646,182	12,925	2.00%	4,416	34.17%
#115 Advising Smokers to Quit	2,218,143	786,087	35.44%	580,067	8,378	1.44%	1,562	18.64%
Upper Respiratory Infection (URI)				185	1	0.54%		
#65 Appropriate Treatment for Children	1	1	100.00%	185	1	0.54%	1	100.00%

^a The number of instances the TIN/NPI was eligible to report the measure. The number of eligible denominator instances found in claims.

^b For each measure, the # of instances where an TIN/NPI combination submitted a valid QDC for that measure.

^c The # of reported instances divided by the eligible cases.

^d The # of unique TIN/NPI combinations meeting denominator criteria for any of the PQRI measures. This includes only valid occurrences of the denominator.

^e The # of eligible NPIs that submitted at least one valid, qualifying QDC used appropriately for a measure.

^f The # of TIN/NPI submitting divided by the # of TIN/NPI eligible.

^g The # of TIN/NPIs who submitted the measure on 80% or greater of eligible instances.

^h The # of TIN/NPI submitting $\geq 80\%$ divided by the # of TIN/NPI submitting.

ⁱ Unduplicated counts of TIN/NPIs (I.e. Clinical Condition/Topic and National totals are a unique count of all TIN/NPIs).

Note: The grayed-out cells do not have a calculated national total.

Note: MCMP and PGP pilot program participants are excluded from these reports (based on the most recent pilot participant list from ORD).

Clinical Condition and Measure	Participant Reporting Information			# Eligible TIN/NPI ^d	TIN/NPI Participation per Measure		# TIN/NPI Submitting ≥80% ^g	% Submitting ≥80% ^h
	Reporting Denominator: Applicable Cases ^a	Numerator: Valid QDCs Reported ^b	National Reporting Rate ^c		# TIN/NPI Submitting ^e	% Total Eligible TIN/NPI Submitting ^f		
Urinary Incontinence (UI)				527,871	5,657	1.07%		
#48 Assessment of Presence or Absence of UI in Women Aged 65 Years and Older	641,403	214,629	33.46%	527,691	5,442	1.03%	1,151	21.15%
#49 Characterization of UI in Women Aged 65 Years and Older	70,593	46,109	65.32%	125,221	1,760	1.41%	703	39.94%
#50 Plan of Care for UI in Women Aged 65 Years and Older	66,756	42,966	64.36%	125,221	1,667	1.33%	641	38.45%
Wound Care				7,836	34	0.43%		
#186 Wound Care: Use of Compression System in Patients with Venous Ulcers	596	263	44.13%	7,836	34	0.43%	11	32.35%
National Totalⁱ				1,004,865	185,153	18.43%	120,783	65.23%

^a The number of instances the TIN/NPI was eligible to report the measure. The number of eligible denominator instances found in claims.

^b For each measure, the # of instances where an TIN/NPI combination submitted a valid QDC for that measure.

^c The # of reported instances divided by the eligible cases.

^d The # of unique TIN/NPI combinations meeting denominator criteria for any of the PQRI measures. This includes only valid occurrences of the denominator.

^e The # of eligible NPIs that submitted at least one valid, qualifying QDC used appropriately for a measure.

^f The # of TIN/NPI submitting divided by the # of TIN/NPI eligible.

^g The # of TIN/NPIs who submitted the measure on 80% or greater of eligible instances.

^h The # of TIN/NPI submitting ≥80% divided by the # of TIN/NPI submitting.

ⁱ Unduplicated counts of TIN/NPIs (i.e. Clinical Condition/Topic and National totals are a unique count of all TIN/NPIs).

Note: The grayed-out cells do not have a calculated national total.

Note: MCMP and PGP pilot program participants are excluded from these reports (based on the most recent pilot participant list from ORD).